DUBLIN--(BUSINESS WIRE)--The "Clinical Decision Support Systems Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report ...
DUBLIN--(BUSINESS WIRE)--The "Ophthalmic Imaging Equipment Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's ...
Dublin, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The "Project Insight - Global Port Construction Projects (Q4 2025)" report has been added to ResearchAndMarkets.com's offering. The analyst is currently ...
3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs. The ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (BPMC) (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in port construction are strongest in South-East Asia and South Asia with large pipelines, particularly in later development stages. Focus on projects in ...
3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...
Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a bid to augment its portfolio in cardiovascular, renal, and metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results